Metaglip and Avandamet for type 2 diabetes.
D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005252:Fees, Pharmaceutical; D005913:Glipizide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
D004338:Drug Combinations; D007004:Hypoglycemic Agents; D013844:Thiazoles; C471073:metaglip; C471074:rosiglitazone-metformin combination; D008687:Metformin; D005913:Glipizide